LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer

Poly-ADP Ribose Polymerase (PARP) targeted therapy is clinically approved for the treatment of homologous recombination (HR) repair deficient tumors. The remarkable success of this therapy in the treatment of HR repair deficient cancers has not translated to HR-proficient cancers. Our studies identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dey, Goutam, Bharti, Rashmi, Braley, Chad, Alluri, Ravi, Esakov, Emily, Crean-Tate, Katie, McCrae, Keith, Joehlin-Price, Amy, Rose, Peter G., Lathia, Justin, Gong, Zihua, Reizes, Ofer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294509/
https://www.ncbi.nlm.nih.gov/pubmed/37370140
http://dx.doi.org/10.1186/s13048-023-01194-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294509/
https://www.ncbi.nlm.nih.gov/pubmed/37370140
http://dx.doi.org/10.1186/s13048-023-01194-2

Ejemplares similares